
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna is projected to increase product sales from $1.73 billion in 2025 to $2.15 billion in 2026, indicating robust revenue growth prospects. The company has recently completed a $1.5 billion debt deal, strengthening its balance sheet and providing enhanced financial flexibility for future opportunities. Additionally, improvements in manufacturing efficiency are expected to potentially expand gross margins by 10% over the next three years, reflecting a positive shift from the gross margin compression experienced during the pandemic.
Bears say
Moderna's financial outlook is negatively impacted by significant declines in COVID vaccine sales, which are projected to decrease from $18 billion in 2022 to $6.7 billion in 2023, alongside reduced guidance for 2025 due to several emerging headwinds. The company's competitive position in new vaccine markets, particularly for RSV, faces challenges from established products such as Arexvy and Abrysvo, further complicating revenue growth prospects. Compounding these issues is the relatively slow advancement of Moderna's pipeline outside of respiratory vaccines, leading to a substantial reduction in their long-term revenue expectations for COVID-related sales from $3.5 billion to $2.5 billion annually.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares